- Home
- EU vs CTMX Comparison
EU vs CTMX Comparison
Compare EU & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EU
- CTMX
- Stock Information
- Founded
- EU 2009
- CTMX 2008
- Country
- EU United States
- CTMX United States
- Employees
- EU N/A
- CTMX N/A
- Industry
- EU Other Metals and Minerals
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- EU Basic Materials
- CTMX Health Care
- Exchange
- EU Nasdaq
- CTMX Nasdaq
- Market Cap
- EU 538.3M
- CTMX 444.3M
- IPO Year
- EU N/A
- CTMX 2015
- Fundamental
- Price
- EU $3.09
- CTMX $2.39
- Analyst Decision
- EU Strong Buy
- CTMX Strong Buy
- Analyst Count
- EU 1
- CTMX 2
- Target Price
- EU $2.75
- CTMX $5.00
- AVG Volume (30 Days)
- EU 2.9M
- CTMX 1.5M
- Earning Date
- EU 08-13-2025
- CTMX 08-07-2025
- Dividend Yield
- EU N/A
- CTMX N/A
- EPS Growth
- EU N/A
- CTMX 128.27
- EPS
- EU N/A
- CTMX 0.49
- Revenue
- EU $46,179,000.00
- CTMX $147,557,000.00
- Revenue This Year
- EU $27.46
- CTMX N/A
- Revenue Next Year
- EU $140.12
- CTMX N/A
- P/E Ratio
- EU N/A
- CTMX $4.92
- Revenue Growth
- EU N/A
- CTMX 23.81
- 52 Week Low
- EU $1.01
- CTMX $0.40
- 52 Week High
- EU $4.44
- CTMX $3.10
- Technical
- Relative Strength Index (RSI)
- EU 67.04
- CTMX 51.36
- Support Level
- EU $2.91
- CTMX $2.32
- Resistance Level
- EU $3.20
- CTMX $2.47
- Average True Range (ATR)
- EU 0.17
- CTMX 0.14
- MACD
- EU 0.01
- CTMX -0.02
- Stochastic Oscillator
- EU 83.82
- CTMX 15.79
About EU enCore Energy Corp.
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.